An observational study in Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH) and Congenital Portosystemic Shunt, sponsored by Prof. Valérie Mc Lin. Not yet recruiting at 1 site in Switzerland. Open to participants aged 1 Day to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by Prof. Valérie Mc Lin · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Pulmonary Arterial Hypertension with a site in Switzerland — 12 open to participants now, 16 under way, 2 of them phase 3. Pulmonary Arterial Hypertension · Switzerland.
Among the 37 studies in Pulmonary Arterial Hypertension with a site in Switzerland, this one is one of 11 that started in 2026, is one of 7 observational ones, reaches primary completion later than 15 of the 15 other live ones, and was the 27th registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →12 of the 37 studies in Pulmonary Arterial Hypertension with a site in Switzerland are open now. Recruiting first, the newest first:
Silvia Ulrich · Sites in Switzerland
Ages 18–80
Silvia Ulrich Somaini · Sites in Switzerland
Ages 18+
Silvia Ulrich Somaini · Sites in Switzerland
Ages 18+
Technische Universität Dresden · Sites in Switzerland, Belgium, Germany and 1 more country
Ages 1 wk+
Silvia Ulrich Somaini · Sites in Switzerland
Ages 18–80
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 1 Day to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 12 · Phase 4 1
First in 2004; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 40 across the 30 interventional studies, 490 across the 7 observational. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 37 have an industry lead sponsor. The 10 most frequent:
Prof. Valérie Mc Lin is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Prof. Valérie Mc Lin has 1 study filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
1 of the studies in Pulmonary Arterial Hypertension with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01347216Technische Universität DresdenCOMPERA / COMPERA-KIDS | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Pulmonary Arterial Hypertension with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Congenital portosystemic shunt (CPSS) are rare vascular malformations causing blood from the intestines to bypass the liver and directly flow into body's general circulation. Such liver bypass can cause several health problems, one of the most severe being portopulmonary hypertension (PoPH).
The goal of this study is to identify pathogenic and potentially pathogenic genetic variants in patients who have both CPSS and PoPH. Future research will assess the contribution of these genetic variants to the development of PoPH.
The long-term goal is to use genetic information to identify patients with congenital portosystemic shunts (CPSS) or chronic liver disease who are at risk of developing PoPH to offer anticipatory management.
Children and adult patients with both CPSS and PoPH, as well as their close relatives (patient's parents and siblings) can take part in the study. Genetic variations within each family will be studied.
Patient participant in the IRCPSS, with history of CPSS and PoPH ; both parents of the patient participants; possibly patient siblings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patient + parents+ siblings
Genetic: targeted gene panels analysis · Genetic: whole genome analysis
The following gene panels will be analyzed : pulmonary arterial hypertension ; hereditary hemorrhagic telangiectasia ; congenital heart disease and potentially pathogenic variants in genes previously associated with PoPH in cirrhosis cohort.
Family-based identification of dominant or recessive potentially pathogenic variants.
List of variants from targeted analysis of selected gene panels
presence/absence of pathogenic variants in known genes (pulmonary arterial hypertension ; hereditary hemorrhagic telangiectasia ; congenital heart disease) and potentially pathogenic variants in genes previously associated with PoPH in cirrhosis cohort.
Time frame: From February 2026 to February 2029
List of variants from whole genome analysis
variants identified using family based search for dominant or recessive potentially pathogenic variants
Time frame: Fron February 2026 to August 2029
Plan to share: Undecided — to be determined
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Aug 2029, 42 months later.
Of 64 non-industry observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 31. This study's planned 42 months is below that.
Counting every sponsor, half of 85 studies reached it within 58 months; a quarter within 30 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →
Prof. Valérie Mc Lin